Brief: Regenxbio Q3 License & Royalty Revenue USD 23.605 Million
06/11/2025 12:05
Nov 06 (Reuters) - Regenxbio Q3 operating expenses USD 82.144 million. Q3 net income USD -61.941 million
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics